Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 16/20 | 0.38 |
| ▸ | APOB | P04114 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5061943 | 0.93 | MTTP (0.38) | MTTPAPOBALDH1A1HPGDKMT2A | |
| SCHEMBL5065855 | 0.92 | ALDH1A1 (0.39) | MTTPAPOBALDH1A1HPGDKMT2A | |
| SCHEMBL5066031 | 0.90 | MTTP (0.37) | MTTPAPOBALDH1A1HPGDKMT2A | |
| SCHEMBL5064942 | 0.90 | MTTP (0.36) | MTTPAPOBALDH1A1HPGDKMT2A | |
| SCHEMBL5065169 | 0.89 | MTTP (0.41) | MTTPAPOBALDH1A1HPGDKMT2A | |
| SCHEMBL5064926 | 0.87 | MTTP (0.38) | MTTPAPOBALDH1A1HPGDKMT2A | |
| SCHEMBL5068058 | 0.86 | MTTP (0.38) | MTTPAPOB | |
| SCHEMBL5061948 | 0.85 | MTTP (0.36) | MTTPALDH1A1HPGDKMT2ANTRK1 | |
| SCHEMBL5065877 | 0.84 | MTTP (0.39) | MTTPAPOBALDH1A1HPGDKMT2A | |
| SCHEMBL5062326 | 0.84 | MTTP (0.38) | MTTPAPOBALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1669345-A1 | ESTER DERIVATIVE AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2006-06-14 | — | — | EP | claimed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060205726-A1 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1669345-A1 | ESTER DERIVATIVE AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205726-A1 | Ester derivatives and medical use thereof | MTTP, LIPC, CETP | MTTP 1/4885APOB 39/4885ALDH1A1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.